PMV Pharmaceuticals details 2026 shareholder votes
PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
PMV Pharmaceuticals, Inc. reported the results of its 2026 virtual annual meeting of stockholders. Stockholders elected two Class III directors: David H. Mack, Ph.D. received 15,693,907 votes for and 6,248,461 withheld, while Laurie Stelzer received 11,261,111 votes for and 10,681,257 withheld. Each will serve until the 2029 annual meeting, subject to earlier death, resignation or removal.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 15,015,578 votes for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes. They also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 28,379,108 votes for, 536,302 against and 2,370 abstentions.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for David H. Mack, Ph.D.: 15,693,907 votes
Votes for Laurie Stelzer: 11,261,111 votes
Say-on-pay votes for: 15,015,578 votes
+3 more
6 metrics
Votes for David H. Mack, Ph.D.
15,693,907 votes
Election as Class III director at 2026 annual meeting
Votes for Laurie Stelzer
11,261,111 votes
Election as Class III director at 2026 annual meeting
Say-on-pay votes for
15,015,578 votes
Non-binding advisory approval of executive compensation
Say-on-pay votes against
6,468,718 votes
Non-binding advisory executive compensation vote
Auditor ratification votes for
28,379,108 votes
Ratification of Ernst & Young LLP for fiscal year 2026
Auditor ratification votes against
536,302 votes
Ratification of Ernst & Young LLP for fiscal year 2026
Key Terms
non-binding advisory vote, broker non-vote, independent registered public accounting firm, emerging growth company, +1 more
5 terms
non-binding advisory vote financial
"The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
broker non-vote financial
"FOR | | AGAINST | | ABSTAIN | | BROKER NON-VOTE 15,015,578 | | 6,468,718 | | 458,072 | | 6,975,412"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
independent registered public accounting firm financial
"Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Audit Committee financial
"ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did PMV Pharmaceuticals (PMVP) stockholders decide at the 2026 annual meeting?
PMV Pharmaceuticals stockholders elected two Class III directors, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as independent auditor for 2026. Each proposal received majority support based on votes cast at the virtual 2026 annual meeting.
Which directors were elected at PMV Pharmaceuticals’ 2026 annual meeting and for how long?
Stockholders elected David H. Mack, Ph.D. and Laurie Stelzer as Class III directors. Each will serve until PMV Pharmaceuticals’ 2029 annual meeting of stockholders, and until a successor is duly elected and qualified or earlier death, resignation, or removal under the company’s governance framework.
How did PMV Pharmaceuticals (PMVP) stockholders vote on executive compensation in 2026?
Stockholders approved the compensation of PMV Pharmaceuticals’ named executive officers on a non-binding advisory basis. The vote totals were 15,015,578 for, 6,468,718 against, 458,072 abstentions and 6,975,412 broker non-votes, reflecting majority support for the pay program described in the April 22, 2026 proxy statement.
Which auditing firm did PMV Pharmaceuticals stockholders ratify for fiscal 2026?
Stockholders ratified Ernst & Young LLP as PMV Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 28,379,108 votes for, 536,302 against and 2,370 abstentions, indicating strong support for the Audit Committee’s auditor selection.
How often does PMV Pharmaceuticals hold advisory votes on executive compensation?
PMV Pharmaceuticals conducts non-binding advisory votes on executive compensation every year. This annual policy followed stockholder approval of the frequency at the 2022 annual meeting and will remain in effect until the next frequency vote, expected at the company’s 2028 annual meeting of stockholders.
What were the broker non-vote totals at PMV Pharmaceuticals’ 2026 annual meeting?
Broker non-votes totaled 6,975,412 shares on the director elections and the advisory vote on executive compensation. There were no broker non-votes reported on the ratification of Ernst & Young LLP, which received votes classified only as for, against, or abstain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
